- Home
- PROK vs DALN Comparison
PROK vs DALN Comparison
Compare PROK & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- DALN
- Stock Information
- Founded
- PROK 2015
- DALN 1954
- Country
- PROK United States
- DALN United States
- Employees
- PROK N/A
- DALN N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- DALN Newspapers/Magazines
- Sector
- PROK Health Care
- DALN Consumer Discretionary
- Exchange
- PROK Nasdaq
- DALN Nasdaq
- Market Cap
- PROK 85.5M
- DALN 72.6M
- IPO Year
- PROK N/A
- DALN 2008
- Fundamental
- Price
- PROK $3.27
- DALN $13.72
- Analyst Decision
- PROK Buy
- DALN
- Analyst Count
- PROK 5
- DALN 0
- Target Price
- PROK $6.25
- DALN N/A
- AVG Volume (30 Days)
- PROK 37.1M
- DALN 333.5K
- Earning Date
- PROK 08-08-2025
- DALN 07-29-2025
- Dividend Yield
- PROK N/A
- DALN N/A
- EPS Growth
- PROK N/A
- DALN N/A
- EPS
- PROK N/A
- DALN 5.55
- Revenue
- PROK $306,000.00
- DALN $123,414,000.00
- Revenue This Year
- PROK $85.21
- DALN N/A
- Revenue Next Year
- PROK N/A
- DALN N/A
- P/E Ratio
- PROK N/A
- DALN $2.49
- Revenue Growth
- PROK N/A
- DALN N/A
- 52 Week Low
- PROK $0.46
- DALN $2.98
- 52 Week High
- PROK $7.13
- DALN $13.80
- Technical
- Relative Strength Index (RSI)
- PROK 62.08
- DALN 93.25
- Support Level
- PROK $3.17
- DALN $13.63
- Resistance Level
- PROK $4.05
- DALN $13.80
- Average True Range (ATR)
- PROK 1.00
- DALN 0.21
- MACD
- PROK 0.13
- DALN 0.87
- Stochastic Oscillator
- PROK 43.10
- DALN 99.12
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company. It operates The Dallas Morning News (dallasnews.com), Texas' newspaper. These operations generate revenue from advertising sales within the company's newspaper and digital platforms, subscriptions and retail sales of its newspaper, and commercial printing and distribution services predominantly related to national newspapers. In addition to traditional print and digital advertising, the company has a full-service agency, Medium Giant, offering businesses comprehensive, strategic, and creative marketing solutions. The company's two reportable segments are TDMN and Agency. Maximum revenue is derived from the TDMN segment, which comprises its traditional print business. The firm's customer base is concentrated in North Texas.